Sharing RareNote PSP's AI Autopilot Case

"Document Review Time Reduced by 60 Percent"

Healthcare data company LifeX announced on the 1st that it will hold the 'LifeX Pharmaceutical Industry AX·DX Seminar' online on the 8th, targeting professionals in the pharmaceutical industry.


Promotional material for the "LIFEX Pharmaceutical Industry AX·DX Seminar" held on the 8th. LIFEX

Promotional material for the "LIFEX Pharmaceutical Industry AX·DX Seminar" held on the 8th. LIFEX

View original image

This seminar will share the background of development and operational outcomes of the AI Autopilot introduced to RareNote, a platform for cancer and rare disease patients, under the theme of 'AX-based cases for enhancing pharmaceutical companies' patient accessibility: Focusing on PSP.' Registration can be completed through the official LifeX application page.


RareNote is a platform that provides medical information to cancer and rare disease patients and their families. There are approximately 55,000 users in Korea. The AI Autopilot has been applied to support work involving the review and assessment of documents for Patient Support Programs (PSPs) that pharmaceutical companies operate to reduce patients’ financial burdens and improve treatment accessibility.


Last year, RareNote transitioned PSP operations from paper documents and mail to a mobile app-based system. From the submission of applications, medical certificates, and receipts, to review and support payment, the entire process can now be managed through the app. However, work requiring staff to directly verify and compare different document formats by hospital and medical department remained a bottleneck.


The company explained that it introduced the AI Autopilot to address this issue. The AI recognizes submitted documents, cross-verifies application information, submitted files, and existing support records, and classifies cases with inconsistencies as high-priority for staff review. According to LifeX, after the launch of AI Autopilot, the time needed for document assessment per case was reduced by more than 60 percent.



Jang Wonyoung, RareNote's PSP Operations Lead, stated, "Our fundamental policy is that while AI supports document review, the final decision will always be made by staff. The cost savings from operational efficiency will also be reflected in lower fees, reducing the operational burden on pharmaceutical companies and enabling patients to receive the support they need even more quickly."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing